- ADVERTISEMENT
-
Most Popular
- ADVERTISEMENT
VVUS
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are.
5 Reasons Why VIVUS, Inc. (VVUS) Stock Should Be in Your Portfolio
VIVUS is a biopharmaceutical company developing and commercializing innovative, next-generation therapies. Here's why VVUS stock is a must
17 Pharmaceuticals Stocks to Sell Now
This week, the ratings of 17 Pharmaceuticals stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
26 Pharmaceuticals Stocks to Sell Now
The ratings of 26 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
13 Pharmaceuticals Stocks to Sell Now
The ratings of 13 Pharmaceuticals stocks are down this week, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
14 Pharmaceuticals Stocks to Sell Now
The overall ratings of 14 Pharmaceuticals stocks are down on Portfolio Grader this week. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
12 Pharmaceuticals Stocks to Sell Now
This week, 12 Pharmaceuticals stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
Vivus, Inc.: Don’t Overthink This Bullish Move in VVUS
Surprise! Vivus stock has been one of the market's hottest names since September. Maybe we should trust the guy making it happen.
5 Best Stocks Under $5 This Week
Envivio, Vivus, Medovex, One Group Hospitality and VolitionRX were among a number of cheap stocks that charged significantly higher this week.
Vivus, Inc. (VVUS): Earnings Preview
The VIVUS earnings report coming on Monday could be a harsh reality check about the long-term prospects for Qsymia.
Orexigen (OREX) Stock Shoots Higher as Contrave Goes on Sale
Orexigen's Contrave joined a couple other FDA-approved weight-loss treatments on the market ... and the OREX product is a serious player.
20 Cheap Stocks Under $10 Worth Zilch
Cheap stocks under $10 are tempting because of their low share price, but some picks are cheap for a reason. Avoid these "bargain" stocks!
Mannkind (MNKD) – Right Stock, Wrong Time
Ten years' worth of work from Mannkind Corporation on Afrezza has just been validated, but that doesn't automatically make the stock a good bet right here, and right now.
3 Pharmaceutical Stocks to Sell Now
This week, the overall grades of three pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
3 Pharmaceutical Stocks to Sell Now
This week, the overall grades of three pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
3 Pharmaceutical Stocks to Sell Now
This week, the overall grades of three pharmaceutical stocks are lower, according to the Portfolio Grader database. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
3 Pharmaceutical Stocks to Sell Now
For the current week, the overall ratings of three pharmaceutical stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
3 Pharmaceutical Stocks to Sell Now
For the current week, the overall ratings of three pharmaceutical stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
